A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing–remitting multiple sclerosis (TIME MS)

Background: Mycophenolate mofetil (MMF) is an oral DNA base synthesis inhibitor with immunomodulatory effects on B cells, T cells, and macrophages. Objective: To conduct a safety and tolerability pilot study of interferon beta-1a (IFN-b1a) in combination with either placebo or oral MMF in multiple s...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Remington, Gina M., Treadaway, Katherine, Frohman, Teresa, Salter, Amber, Stüve, Olaf, Racke, Michael K., Hawker, Kathleen, Agosta, Federica, Sormani, Maria Pia, Filippi, Massimo, Frohman, Elliot M.
Format: Artigo
Sprache:Inglês
Veröffentlicht: SAGE Publications 2010
Schlagworte:
Original Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3002615/
https://ncbi.nlm.nih.gov/pubmed/21180632
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756285609355851
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge